pCODR Releases Initial Recommendation of Opdivo

pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.

This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer.

Read more
Initial Recommendation (pdf)